Transcriptomic analysis identifies FABP5 as a candidate regulator of lipid accumulation in metabolic dysfunction-associated fatty liver disease
Hematic Fabp5 expression and circulating FABP5 concentrations are reduced in experimental and human MAFLD, suggesting that FABP5 is a candidate regulator of hepatic lipid metabolism and warrants further investigation as a potential therapeutic target.